Enrolling by invitationNot applicableNCT07221773

Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Principal Investigator
Melissa Y Rayner, MS, M.D
Restore Biologics Holding, Inc dba Xtressé
Intervention
XVIE(other)
Enrollment
15 target
Eligibility
28-65 years · FEMALE
Timeline
20252026

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07221773 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials